TY - THES A1 - Bittorf, Patrick T1 - Entwicklung, Herstellung und präklinisches Studienprogramm für ein Arzneimittel für neuartige Therapien zur Behandlung der schweren Form der Hämophilie A T1 - Development, manufacturing and preclinical study program for an Advanced Therapy Medicinal Product for the treatment of severe hemophilia A N2 - Bevor ein zellbasiertes GTMP erstmalig beim Menschen angewendet werden kann, müssen verschiedene notwendige nicht-klinische Studien durchgeführt werden. Wichtig ist hier u.a. die Untersuchung der Biodistribution im Tiermodel. Diese umfasst die Verteilung, das Engraftment, die Persistenz, die Eliminierung und gegebenenfalls die Expansion der humanen Zellen in verschiedenen Organen, meistens im Mausmodel. Deshalb wurde eine qPCR-basierte Analysenmethode entwickelt, mit der humane genomische DNA innerhalb von muriner genomischer DNA bestimmt werden kann, und entsprechend den regulatorischen Richtlinien der European Medicines Agency und des International Council for Harmonisation validiert. Anschließend wurde diese Methode innerhalb einer präklinischen worst-case Szenario Biodistributionsstudie angewendet. Das Ziel dieser Studie war die Untersuchung des Biodistributionsprofils von genetisch modifizierten Blood Outgrowth Endothelial Cells von Hämophilie A Patienten 24 Stunden und sieben Tage nach intravenöser Applikation einer Dosis von 2x106 Zellen. Die Isolation, genetische Modifikation und die Expansion der Zellen sollte entsprechend den Richtlinien der Guten Herstellungspraxis durchgeführt werden. Hierbei ist die Auswahl und Anwendung geeigneter und essentieller Rohstoffe wichtig. Gleichermaßen ist die Durchführung einer definierten Qualitätskontrollstrategie notwendig und die Patientenzellen sollten nur innerhalb von nicht-klinischen Studien eingesetzt werden, wenn alle Akzeptanzkriterien erfüllt wurden. Die Validierung der qPCR-Methode zeigte eine hohe Genauigkeit, Präzision und Linearität innerhalb des Konzentrationsintervalls von 1:1x103 bis 1:1x106 humanen zu murinen Genomen. Bei Anwendung dieser Methode für die Biodistributionsstudie konnten nach 24 Stunden humane Genome in vier der acht untersuchten Mausorgane bestimmt werden. Nach sieben Tagen konnten in keinem der acht Organe humane Genome nachgewiesen werden... N2 - The mandatory non-clinical study scheme prior to the first administration of a cell-based gene therapy medicinal product (GTMP) to human subjects includes and requires investigation of the biodistribution, comprising mobilization, persistence, and clearance, of the GTMP in a relevant animal model. Therefore, a qPCR-based method to determine the amount of human DNA in mouse DNA was developed and validated according to the guidelines of the European Medicines Agency and the International Council for Harmonisation. Furthermore, a preclinical worst-case scenario study was performed, in which this method was applied to investigate the biodistribution of 2x106 intravenously administered, genetically modified blood outgrowth endothelial cells from hemophilia A patients after 24 hours and seven days. The isolation, genetic modification and expansion of cells should be performed according to the guidelines on Good Manufacturing Practice. Here, the selection and application of appropriate and necessary raw materials is important. Likewise, the performance of a defined quality control program is mandatory and cells should only be applied within non-clinical studies if they passed all acceptance criteria. The validation of the qPCR method demonstrated high accuracy, precision, and linearity for the concentration interval of 1:1x103 to 1:1x106 human to mouse genomes. The application of this method in the biodistribution study resulted in the detection of human genomes in four out of the eight investigated organs after 24 hours. After seven days, no human DNA was detected in the eight organs analyzed. This biodistribution study provides mandatory data on the toxicokinetic safety profile of an actual cell-based medicinal product candidate. This is a prerequisite for designing and performing the subsequent toxicity studies necessary to ensure patient safety and permit moving the medicinal product towards a first-in-human clinical trial. KW - Arzneimittel KW - QPCR KW - GMP KW - Validierung KW - Hämophilie A KW - Neuartige Arzneimittel KW - Präklinische Studien KW - Biodistribution KW - Arzneimittelzulassung KW - Advanced Therapy Medicinal Products (ATMP) KW - Preclinical studies KW - Biodistribution KW - Marketing authorisation of pharmaceuticals Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-231858 ER - TY - JOUR A1 - Haeusner, Sebastian A1 - Herbst, Laura A1 - Bittorf, Patrick A1 - Schwarz, Thomas A1 - Henze, Chris A1 - Mauermann, Marc A1 - Ochs, Jelena A1 - Schmitt, Robert A1 - Blache, Ulrich A1 - Wixmerten, Anke A1 - Miot, Sylvie A1 - Martin, Ivan A1 - Pullig, Oliver T1 - From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product JF - Frontiers in Medicine N2 - Advanced Therapy Medicinal Products (ATMP) provide promising treatment options particularly for unmet clinical needs, such as progressive and chronic diseases where currently no satisfying treatment exists. Especially from the ATMP subclass of Tissue Engineered Products (TEPs), only a few have yet been translated from an academic setting to clinic and beyond. A reason for low numbers of TEPs in current clinical trials and one main key hurdle for TEPs is the cost and labor-intensive manufacturing process. Manual production steps require experienced personnel, are challenging to standardize and to scale up. Automated manufacturing has the potential to overcome these challenges, toward an increasing cost-effectiveness. One major obstacle for automation is the control and risk prevention of cross contaminations, especially when handling parallel production lines of different patient material. These critical steps necessitate validated effective and efficient cleaning procedures in an automated system. In this perspective, possible technologies, concepts and solutions to existing ATMP manufacturing hurdles are discussed on the example of a late clinical phase II trial TEP. In compliance to Good Manufacturing Practice (GMP) guidelines, we propose a dual arm robot based isolator approach. Our novel concept enables complete process automation for adherent cell culture, and the translation of all manual process steps with standard laboratory equipment. Moreover, we discuss novel solutions for automated cleaning, without the need for human intervention. Consequently, our automation concept offers the unique chance to scale up production while becoming more cost-effective, which will ultimately increase TEP availability to a broader number of patients. KW - ATMP KW - tissue engineering KW - GMP KW - manufacturing KW - autologous KW - cartilage regeneration KW - automation & robotics KW - automation Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-244631 SN - 2296-858X VL - 8 ER - TY - JOUR A1 - Bittorf, Patrick A1 - Bergmann, Thorsten A1 - Merlin, Simone A1 - Olgasi, Chistina A1 - Pullig, Oliver A1 - Sanzenbacher, Ralf A1 - Zierau, Martin A1 - Walles, Heike A1 - Follenzi, Antonia A1 - Braspenning, Joris T1 - Regulatory-Compliant Validation of a Highly Sensitive qPCR for Biodistribution Assessment of Hemophilia A Patient Cells JF - Molecular Therapy - Methods & Clinical Development N2 - The investigation of the biodistribution profile of a cell-based medicinal product is a pivotal prerequisite to allow a factual benefit-risk assessment within the non-clinical to clinical translation in product development. Here, a qPCR-based method to determine the amount of human DNA in mouse DNA was validated according to the guidelines of the European Medicines Agency and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Furthermore, a preclinical worst-case scenario study was performed in which this method was applied to investigate the biodistribution of 2 x 10\(^6\) intravenously administered, genetically modified, blood outgrowth endothelial cells from hemophilia A patients after 24 h and 7 days. The validation of the qPCR method demonstrated high accuracy, precision, and linearity for the concentration interval of 1:1 x 10\(^3\) to 1:1 x 10\(^6\) human to mouse DNA. The application of this method in the biodistribution study resulted in the detection of human genomes in four out of the eight investigated organs after 24 h. After 7 days, no human DNA was detected in the eight organs analyzed. This biodistribution study provides mandatory data on the toxicokinetic safety profile of an actual candidate cell-based medicinal product. The extensive evaluation of the required validation parameters confirms the applicability of the qPCR method for non-clinical biodistribution studies. KW - outgrowth endothelial cells KW - real time PCR KW - in vivo KW - gene therapy KW - factor-VIII KW - murine KW - quantification KW - establishment KW - phenotype KW - xenotransplantation Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230284 VL - 18 ER -